No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study

Abstract

Background:

No evidence of disease activity (NEDA) is a composite endpoint being increasingly applied as an outcome measure in clinical trials as well as proposed for individual therapeutic decisions in multiple sclerosis (MS).

Objective:

Assess the proportion of patients with relapsing-remitting MS achieving NEDA in the DECIDE study of daclizumab 150 mg subcutaneous versus intramuscular interferon beta-1a 30 µg for 96–144 weeks.

Methods:

NEDA was defined as no relapses, no onset of 12-week confirmed disability progression (CDP), no new/newly enlarging T2 hyperintense lesions (NET2), and no gadolinium-enhancing (Gd⁺) lesions. Logistic regression models adjusted for baseline covariates compared treatment groups for baseline to week 96, weeks 0–24, and weeks 24–96.

Results:

From baseline to week 96, more daclizumab versus intramuscular interferon beta-1a patients achieved NEDA (24.6% vs 14.2%; odds ratio (OR; 95% confidence interval): 2.059 (1.592−2.661); p < 0.0001). ORs for clinical NEDA (no relapses, no CDP) and magnetic resonance imaging (MRI) NEDA (no NET2, no Gd⁺ lesions) were 1.651 (1.357−2.007; p < 0.0001) and 2.051 (1.628−2.582; p < 0.0001), respectively. ORs in favor of daclizumab for weeks 24–96 were consistently higher than for weeks 0–24.

Conclusion:

More daclizumab versus intramuscular interferon beta-1a patients achieved NEDA early in DECIDE, with effects increasing over time.

Keywords

Composite outcome daclizumab clinical endpoints disease-activity-free magnetic resonance imaging no evidence of disease activity radiological endpoints relapsing-remitting multiple sclerosis treatment

Get full access to this article

View all access options for this article.

References

Giovannoni

Turner

Gnanapavan

et al . Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord 2015; 4: 329–333.

Bevan

Cree

. Disease activity free status: A new end point for a new era in multiple sclerosis clinical research? JAMA Neurol 2014; 71: 269–270.

Stangel

Penner

Kallmann

et al . Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: The multiple sclerosis decision model. Ther Adv Neurol Disord 2015; 8: 3–13.

Havrdova

Galetta

Hutchinson

et al . Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: A retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009; 8: 254–260.

Arnold

Calabresi

Kieseier

et al . Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: Results from a randomized controlled trial in relapsing-remitting multiple sclerosis. BMC Neurol 2014; 14: 240.

Havrdova

Giovannoni

Stefoski

et al . Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. Mult Scler 2014; 20: 464–470.

Cohen

Khatri

Barkhof

et al . (; TRANSFORMS (TRial Assessing injectable interferoN vS. FTY720 Oral in RRMS) Study Group.) Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: Results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry 2016; 87: 468–475.

Freedman

. Are we in need of NEDA? Mult Scler 2016; 22: 5–6.

Rotstein

Healy

Malik

et al . Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol 2015; 72: 152–158.

10.

Cree

Gourraud

Oksenberg

et al . Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol 2016; 80: 499–510.

11.

Fox

Chan

Zhang

et al . Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis. Curr Med Res Opin. Epub ahead of print 10 November 2016. DOI: 10.1080/03007995.2016.1248380.

12.

Sormani

Muraro

Saccardi

et al . NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs. Mult Scler 2017; 23: 201–204.

13.

Nygaard

Celius

de Rodez Benavent

et al . A longitudinal study of disability, cognition and gray matter atrophy in early multiple sclerosis patients according to evidence of disease activity. PLoS ONE 2015; 10: e0135974.

14.

Uher

Havrdova

Sobisek

et al . Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up? Mult Scler 2017; 23: 242–252.

15.

Prosperini

Fanelli

Pozzilli

. Long-term assessment of no evidence of disease activity with natalizumab in relapsing multiple sclerosis. J Neurol Sci 2016; 364: 145–147.

16.

Elkins

Sheridan

Amaravadi

et al . CD56^bright natural killer cells and response to daclizumab HYP in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm 2015; 2: e65.

17.

Gold

Giovannoni

Selmaj

et al .(; SELECT study investigators.) Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): A randomised, double-blind, placebo-controlled trial. Lancet 2013; 381: 2167–2175.

18.

Wiendl

Gross

. Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis. Nat Rev Neurol 2013; 9: 394–404.

19.

Kappos

Wiendl

Selmaj

et al . Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 2015; 373: 1418–1428.

20.

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: Guideline for good clinical practice, http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf (1996, accessed 2 February 2015).

21.

Prosperini

Gianni

Barletta

et al . Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis. J Neurol Sci 2012; 323: 104–112.

22.

Kappos

De Stefano

Freedman

et al . Inclusion of brain volume loss in a revised measure of “no evidence of disease activity” (NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler 2016; 22: 1297–1305.

23.

Miller

Grossman

Reingold

et al . The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998;121(pt 1): 3–24.

24.

Jacobs

Cookfair

Rudick

et al .; CLARITY study group. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285–294.

25.

Lublin

. Disease activity free status in MS. Mult Scler Relat Disord 2012; 1: 6–7.

26.

Giovannoni

Cook

Rammohan

et al . (; CLARITY study group.) Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: A post-hoc and subgroup analysis. Lancet Neurol 2011; 10: 329–337.

27.

Giovannoni

Arnold

Cohen

et al . Disease activity-free status in comparison of Alemtuzumab and Rebif^® efficacy in multiple sclerosis I (CARE-MS I) phase 3 study. J Neurol 2012; 259(Suppl. 1): S47.

28.

Freedman

O’Connor

Wolinsky

et al . Teriflunomide increases the proportion of patients free from disease activity in the TEMSO phase III study. Neurology 2012; 78(meeting abstracts1): PD5.007.

29.

Lavery

Verhey

Waldman

. Outcome measures in relapsing-remitting multiple sclerosis: Capturing disability and disease progression in clinical trials. Mult Scler Int 2014; 2014: 262350.

30.

Polman

Rudick

. The multiple sclerosis functional composite: A clinically meaningful measure of disability. Neurology 2010; 74 (Suppl. 3): S8–S15.

31.

Sloane

Mainero

Kinkel

. No evidence of disease activity in multiple sclerosis. JAMA Neurol 2015; 72: 835–836.

32.

Imitola

Racke

. Is no evidence of disease activity a realistic goal for patients with multiple sclerosis? JAMA Neurol 2015; 72: 145–147.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.51 MB